Profile data is unavailable for this security.
About the company
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
- Revenue in USD (TTM)0.00
- Net income in USD-246.18k
- Incorporated2008
- Employees0.00
- LocationNexien Biopharma Inc4340 E Kentucky Ave Ste 206GLENDALE 80246-2067United StatesUSA
- Phone+1 (303) 495-7583
- Fax+1 (302) 645-1280
- Websitehttps://nexienbiopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Inc | 115.66m | -263.43m | 869.47k | 102.00 | -- | -- | -- | 0.0075 | -212.10 | -212.10 | 93.13 | -149.56 | 0.5068 | 1.14 | 12.59 | 1,133,961.00 | -115.42 | -26.62 | -266.35 | -31.97 | 86.38 | 78.22 | -227.75 | -111.91 | 0.1533 | -0.692 | 33.57 | -- | -0.7869 | -24.24 | -283.60 | -- | -62.13 | -- |
| Neutra Corp | 17.40k | -474.98k | 875.37k | -- | -- | -- | -- | 50.31 | -0.0002 | -0.0002 | 0.00001 | -0.0003 | 0.2786 | 0.4126 | -- | -- | -758.75 | -682.94 | -- | -- | 46.15 | -- | -2,723.22 | -2,758.85 | 0.0009 | -14.06 | -- | -- | -26.09 | -- | 22.28 | -- | -- | -- |
| Kaya Holdings Inc | 196.30k | 1.61m | 886.91k | 2.00 | 0.5711 | -- | 0.5381 | 4.52 | 0.07 | 0.07 | 0.0038 | -0.6222 | 0.3707 | 7.66 | -- | 98,150.00 | 309.03 | 28.68 | -- | -- | 58.56 | 65.75 | 833.66 | 66.12 | 0.0118 | -- | -- | 0.00 | -71.36 | -29.62 | 145.01 | -19.45 | -- | -- |
| Evofem Biosciences Inc | 16.01m | 47.49m | 888.08k | 37.00 | 0.0015 | -- | 0.0186 | 0.0555 | -5.92 | -5.92 | 0.0826 | -1.36 | 0.935 | 1.72 | 2.73 | 432,756.80 | 295.02 | -211.64 | -- | -- | 63.65 | -- | 315.54 | -1,031.55 | 0.0757 | -2.91 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| Comera Life Sciences Holdings Inc | 1.00m | -9.35m | 899.08k | 12.00 | -- | -- | -- | 0.8987 | -0.4901 | -0.4901 | 0.0512 | 0.0033 | 0.2498 | -- | 5.08 | 83,367.50 | -224.98 | -- | -1,094.30 | -- | 73.52 | -- | -900.55 | -- | -- | -- | 0.00 | -- | 97.95 | -- | -237.10 | -- | -- | -- |
| Sunshine Biopharma Inc | 24.09m | -4.51m | 974.64k | 44.00 | -- | 0.013 | -- | 0.0405 | -19.07 | -19.07 | 99.47 | 75.68 | 0.8515 | 3.49 | 10.79 | 547,563.40 | -15.92 | -101.52 | -20.43 | -137.04 | 34.61 | 35.47 | -18.70 | -165.33 | 3.45 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| Cannabis Suisse Corp | 30.00k | -254.75k | 987.43k | -- | -- | -- | -- | 32.91 | -0.0057 | -0.0057 | 0.0007 | -0.0103 | 0.0675 | -- | -- | -- | -57.35 | -149.71 | -238.71 | -- | 8.37 | -39.11 | -849.17 | -427.20 | -- | -13.57 | 3.38 | -- | 28.70 | 9.00 | -87.10 | -- | -- | -- |
| Limitless X Holdings Inc | 20.06m | -16.12m | 1.00m | 12.00 | -- | -- | -- | 0.05 | -4.06 | -4.06 | 5.06 | -3.24 | 3.30 | 2.31 | 39.61 | 1,671,340.00 | -265.35 | -- | -- | -- | 77.66 | -- | -80.37 | -- | 0.0186 | -15.77 | -- | -- | -65.83 | -- | -60.80 | -- | -- | -- |
| Sativus Tech Corp | 0.00 | -324.00k | 1.04m | -- | -- | -- | -- | -- | -0.1091 | -0.1091 | 0.00 | -0.5418 | 0.00 | -- | -- | -- | -45.82 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | -- | -- | 78.78 | -- | -- | -- |
| Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Nexien Biopharma Inc | 0.00 | -246.18k | 1.10m | 0.00 | -- | -- | -- | -- | -0.0038 | -0.0038 | 0.00 | -0.0048 | 0.00 | -- | -- | -- | -679.40 | -860.53 | -- | -1,653.53 | -- | -- | -- | -- | -- | -1.77 | -- | -- | -- | -- | 42.22 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 1.12m | 3.00 | -- | 0.286 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| Rimrock Gold Corp | 0.00 | -764.61k | 1.15m | 1.00 | -- | -- | -- | -- | -0.0104 | -0.0104 | 0.00 | -0.00008 | 0.00 | -- | -- | -- | -187.26 | -236.34 | -1,424.92 | -366.85 | -- | -- | -- | -83,418.52 | -- | -1.48 | 1.12 | -- | -- | -- | 30.55 | -- | -- | -- |
| Vestiage Inc | 0.00 | -48.93k | 1.22m | 0.00 | -- | -- | -- | -- | -0.0008 | -0.0008 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -13,048.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -102.30 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Nexien Biopharma Inc's reporting currency: US Dollar USD
